Photocure ASA Company Description

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products.

It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer.

It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia.

The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf’s System blue technology.

It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners.

The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, other European countries, Canada, and the United States.

Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.

Photocure ASA

Country	Norway
Founded	1993
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	101
CEO	Daniel Schneider

Contact Details

Address: Hoffsveien 4 Oslo, 0275 Norway
Phone	47 22 06 22 10
Website	photocure.com

Stock Details

Ticker Symbol	PHO
Exchange	Oslo Børs
Fiscal Year	January - December
Reporting Currency	NOK
ISIN Number	NO0010000045
SIC Code	2834

Key Executives

Name	Position
Daniel Schneider	President and Chief Executive Officer
Erik Dahl	Chief Financial Officer
Anja Gossens-von der Heidt	Head of Global Human Resources
Dr. Anders Neijber M.D.	Chief Medical Officer of Global Medical Affairs, Clinical Development and Research & Development
Jane Healy	Vice President and General Manager of Europe
Priyam Shah	????Vice President of Investor Relations
Tolv Hillestad	Group Controller